{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:24Z","timestamp":1793386464435,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.autrev.2026.104091","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:55:36Z","timestamp":1779429336000},"page":"104091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome"],"prefix":"10.1016","volume":"25","author":[{"given":"Mohsen Farjoud","family":"Kouhanjani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Plautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Siebenbrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Str\u00fcber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41582-020-0359-x","article-title":"GAD antibodies in neurological disorders - insights and challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2026.104091_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0015","article-title":"GAD65 antibody-associated epilepsy","volume":"59","author":"Valin\u010di\u016bt\u0117","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200422","article-title":"Temporal lobe epilepsy associated with glutamic acid decarboxylase antibodies","volume":"12","author":"Rada","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.17712\/nsj.2016.3.20150596","article-title":"Anti-glutamic acid decarboxylase antibody positive neurological syndromes","volume":"21","author":"Tohid","year":"2016","journal-title":"Neurosciences (Riyadh)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/08916939409009534","article-title":"Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes","volume":"19","author":"L\u00fchder","year":"1994","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/brain\/awac119","article-title":"A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies","volume":"146","author":"Strippel","year":"2023","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00415-025-12926-3","article-title":"GAD antibodies in neurological disease: a critical evaluation of the utility and treatment implications of GAD antibodies in clinical practice","volume":"272","author":"Brown","year":"2025","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","article-title":"Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases","volume":"122","author":"Reiber","year":"1994","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","article-title":"Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs","volume":"184","author":"Reiber","year":"2001","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0404.2000.102005322.x","article-title":"Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index","volume":"102","author":"Lunding","year":"2000","journal-title":"Acta Neurol Scand"},{"issue":"6856","key":"10.1016\/j.autrev.2026.104091_bb0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.305.6856.769","article-title":"Antenatal screening for Down's syndrome","volume":"305","author":"Spencer","year":"1992","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200125","article-title":"Mesiotemporal volumetry, cortical thickness, and neuropsychological deficits in the long-term course of limbic encephalitis","volume":"10","author":"Harms","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0075","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00259-025-07526-2","article-title":"Longitudinal changes in (18)FFDG PET brain metabolism as a prognostic marker in autoimmune encephalitis","volume":"53","author":"Cerne","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41577-023-00985-4","article-title":"The immunology of type 1 diabetes","volume":"24","author":"Herold","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104091_bb0085","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00125-023-06011-5","article-title":"Quantifying beta cell function in the preclinical stages of type 1 diabetes","volume":"66","author":"Galderisi","year":"2023","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1297\/cpe.23.99","article-title":"Type 1 diabetes and autoimmunity","volume":"23","author":"Kawasaki","year":"2014","journal-title":"Clin Pediatr Endocrinol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41572-022-00390-6","article-title":"Adult-onset autoimmune diabetes","volume":"8","author":"Buzzetti","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.autrev.2026.104091_bb0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.autrev.2026.104091_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq7595","article-title":"Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell-mediated limbic encephalitis","volume":"9","author":"Gallus","year":"2023","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0110","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/brain\/awac404","article-title":"Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex","volume":"146","author":"Tr\u00f6scher","year":"2023","journal-title":"Brain"},{"issue":"23","key":"10.1016\/j.autrev.2026.104091_bb0115","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104091_bb0125","series-title":"Cochrane training","article-title":"Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis","year":"2026"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200148","article-title":"Mimics of autoimmune encephalitis: validation of the 2016 clinical autoimmune encephalitis criteria","volume":"10","author":"van Steenhoven","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/neurosci5020015","article-title":"Characterization of anti-GAD65-associated neurological syndromes: clinical features and antibody titers","volume":"5","author":"Moura","year":"2024","journal-title":"NeuroSci"},{"issue":"10","key":"10.1016\/j.autrev.2026.104091_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103701","article-title":"Neurological syndromes associated with anti-GAD antibodies","volume":"21","author":"Dade","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/epd2.20045","article-title":"Focal epilepsies: update on diagnosis and classification","volume":"25","author":"Nascimento","year":"2023","journal-title":"Epileptic Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104091_bb0150","first-page":"S20","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12874-025-02528-y","article-title":"Using artificial intelligence for systematic review: the example of Elicit","volume":"25","author":"Bernard","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2026.104091_bb0165","author":"Wildemann Bea"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.autrev.2026.104091_bb0175","author":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence"},{"issue":"Pt 10","key":"10.1016\/j.autrev.2026.104091_bb0180","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104091_bb0185","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-025-08330-4","article-title":"Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy","author":"Di Giacomo","year":"2025","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200151","article-title":"Cenobamate and Clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies","volume":"10","author":"Serrano-Castro","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ane.13281","article-title":"Clinical characteristics of GAD 65-associated autoimmune encephalitis","volume":"142","author":"Zhu","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2026.104091_bb0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jneuroim.2018.01.007","article-title":"Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: a comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus","volume":"317","author":"Nakajima","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13023-018-0787-5","article-title":"GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies","volume":"13","author":"Liimatainen","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104091_bb0210","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1440-1754.2008.01387.x","article-title":"Does epilepsy occur more frequently in children with type 1 diabetes?","volume":"44","author":"O\u2019Connell","year":"2008","journal-title":"J Paediatr Child Health"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0215","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1468-1331.2011.03609.x","article-title":"Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies","volume":"19","author":"Falip","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2026.104091_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578670","article-title":"A rare neuroendocrine presentation in pediatric anti-glutamic acid decarboxylase autoimmunity: case report and literature review","volume":"406","author":"Pereira","year":"2025","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0225","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1507\/endocrj.EJ24-0457","article-title":"Glutamic acid decarboxylase antibody-spectrum disorders and type 1 diabetes mellitus in a patient following allogenic hematopoietic cell transplantation with review of literature","volume":"72","author":"Sano","year":"2025","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12883-025-04126-3","article-title":"New-onset drug-resistant epilepsy in type 1 diabetes mellitus patient following COVID-19 vaccination: suspicious for autoimmune pathogenesis","volume":"25","author":"Shaaban","year":"2025","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.37897\/RJN.2024.2.1","article-title":"Exploring the diverse phenotypes of anti-GAD 65 encephalitis, diagnosis and treatment challenges","volume":"23","author":"Dulamea","year":"2024","journal-title":"Rom J Neurol Rev Rom Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0240","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/pjnns.98738","article-title":"Management of autoimmune temporal lobe epilepsy with GAD65 antibody: four case reports","volume":"58","author":"Janszky","year":"2024","journal-title":"Neurol Neurochir Pol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0245","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/ncn3.12830","article-title":"Obsessive-compulsive disorder as an initial manifestation of anti-glutamic acid decarboxylase antibody-associated encephalitis","volume":"12","author":"Yamahara","year":"2024","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.autrev.2026.104091_bb0250","article-title":"The IVIG treatment response in autoimmune polyendocrine syndromes type 2 with anti-GAD65 antibody-associated stiff person syndrome: a case report and literature review","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0255","article-title":"Autoimmune encephalitis with autoimmune diabetes: a case of horror Autotoxicus","volume":"15","author":"Alkaissi","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0260","article-title":"Co-occurrence of anti-GAD65 syndrome, type 1 diabetes mellitus, and focal seizures with impaired awareness","volume":"15","author":"Bach","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2026.104091_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1072075","article-title":"Musicogenic seizures in temporal lobe epilepsy: case reports based on ictal source localization analysis","volume":"14","author":"Bratu","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104091_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1278761","article-title":"Case report: limbic encephalitis following treatment with durvalumab for small-cell lung cancer","volume":"14","author":"Moss","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104091_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1274672","article-title":"A case report of anti-GAD65 antibody-positive autoimmune encephalitis in children associated with autoimmune polyendocrine syndrome type-II and literature review","volume":"14","author":"Sapana","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000519229","article-title":"Clinical heterogeneity in acute symptomatic seizures due to autoimmune encephalitis related to GAD65 antibodies","volume":"29","author":"Fan","year":"2022","journal-title":"Neuroimmunomodulation"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0285","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab188","article-title":"Intractable seizures and limbic encephalitis, unaccounted complications of type 1 diabetes autoimmunity","volume":"6","author":"Madkhali","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.autrev.2026.104091_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.756668","article-title":"Case report: multisystem autoimmune and overlapping GAD65-antibody-associated neurological disorders with beneficial effect of epilepsy surgery and rituximab treatment","volume":"12","author":"Dimova","year":"2022","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-237913","article-title":"Rare presentation of anti-GAD-65 antibody-positive autoimmune encephalitis and simultaneous onset of type 1 diabetes mellitus in a paediatric patient","volume":"14","author":"Kern","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0300","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/ene.14692","article-title":"Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy","volume":"28","author":"Piepgras","year":"2021","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0305","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1515\/jpem-2019-0395","article-title":"GAD-65 autoantibody associated epilepsy","volume":"33","author":"Dimova","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0310","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ccr3.2538","article-title":"Autoimmune musicogenic epilepsy associated with anti-glutamic acid decarboxylase antibodies and stiff-person syndrome","volume":"8","author":"Jesus-Ribeiro","year":"2020","journal-title":"Clin Case Reports"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12868-020-00561-9","article-title":"Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?","volume":"21","author":"Li","year":"2020","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.autrev.2026.104091_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102331","article-title":"Large hemispheric lesions in autoimmune encephalitis associated with anti-GAD 65 antibodies","volume":"44","author":"Sianati","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3805\/eands.11.15","article-title":"A case of musicogenic epilepsy with high level of anti-glutamic acid decarboxylase antibodies","volume":"11","author":"Goji","year":"2019","journal-title":"Epilepsy Seizure"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0330","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1684\/epd.2019.1094","article-title":"GAD65-Ab encephalitis and subtle focal status epilepticus","volume":"21","author":"Goudot","year":"2019","journal-title":"Epileptic Disord"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0335","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.braindev.2018.10.006","article-title":"Severe anti-GAD antibody-associated encephalitis after stem cell transplantation","volume":"41","author":"Nagai","year":"2019","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0340","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1753-0407.12627","article-title":"Latent autoimmune diabetes and limbic encephalitis with antibodies against glutamic acid decarboxylase","volume":"10","author":"Popkirov","year":"2018","journal-title":"J Diabetes"},{"key":"10.1016\/j.autrev.2026.104091_bb0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2016.02.006","article-title":"Refractory status epilepticus and autoimmune encephalitis with GABAAR and GAD65 antibodies: a case report","volume":"37","author":"Gagnon","year":"2016","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0350","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/pedi.12346","article-title":"Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies","volume":"17","author":"Ganelin-Cohen","year":"2016","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0355","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1515\/jpem-2016-0016","article-title":"Type 1 diabetes and GAD65 limbic encephalitis: a case report of a 10-year-old girl","volume":"29","author":"Grilo","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0360","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/0972-2327.165462","article-title":"A unique combination of autoimmune limbic encephalitis, type 1 diabetes, and stiff person syndrome associated with GAD-65 antibody","volume":"19","author":"Sharma","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0365","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13760-014-0332-9","article-title":"Idiopathic limbic encephalitis associated with antibodies to glutamic acid decarboxylase","volume":"115","author":"Millet","year":"2015","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0370","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1212\/CPJ.0000000000000148","article-title":"Anti-GAD antibody syndrome with concomitant cerebellar ataxia, stiff person syndrome, and limbic encephalitis","volume":"5","author":"Schaefer","year":"2015","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.autrev.2026.104091_bb0375","first-page":"2014","article-title":"Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis","author":"Georgieva","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"7\u20138","key":"10.1016\/j.autrev.2026.104091_bb0380","first-page":"269","article-title":"Anti glutamate-decarboxylase antibodies: a liaison between localisation related epilepsy, stiff-person syndrome and type-1 diabetes mellitus","volume":"67","author":"Sz\u0171cs","year":"2014","journal-title":"Ideggyogy Sz"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0385","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diabet.2012.02.005","article-title":"Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy","volume":"38","author":"Lopez-Sublet","year":"2012","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0390","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/archneurol.2011.177","article-title":"Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: a treatable condition?","volume":"68","author":"Korff","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0395","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/j.1468-1331.2009.02839.x","article-title":"Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment","volume":"17","author":"Nociti","year":"2010","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0400","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-010-5476-9","article-title":"Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil","volume":"257","author":"Saidha","year":"2010","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0405","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10072-009-0122-y","article-title":"Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep","volume":"30","author":"Baglietto","year":"2009","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104091_bb0410","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jneuroim.2008.05.015","article-title":"Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies","volume":"199","author":"Mat\u00e0","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104091_bb0415","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2169\/internalmedicine.44.1174","article-title":"Type 1 diabetes mellitus and drug-resistant epilepsy: presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid","volume":"44","author":"Yoshimoto","year":"2005","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0420","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1542\/peds.109.3.e50","article-title":"Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies","volume":"109","author":"Olson","year":"2002","journal-title":"Pediatrics"},{"issue":"16","key":"10.1016\/j.autrev.2026.104091_bb0425","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJM198804213181602","article-title":"Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus","volume":"318","author":"Solimena","year":"1988","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0430","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4274\/jcrpe.3818","article-title":"Autoimmune limbic encephalitis associated with type 1 diabetes mellitus","volume":"9","author":"Ak\u0131n","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0435","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","article-title":"Clinical spectrum of high-titre GAD65 antibodies","volume":"92","author":"Budhram","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0440","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00415-020-09807-2","article-title":"Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies","volume":"267","author":"Joubert","year":"2020","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0445","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/dmrr.420","article-title":"Gender differences in GAD antibody-positive diabetes mellitus in relation to age at onset, C-peptide and other endocrine autoimmune diseases","volume":"20","author":"Lindholm","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"10.1016\/j.autrev.2026.104091_bb0450","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00125-020-05276-4","article-title":"Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells","volume":"63","author":"Johnson","year":"2020","journal-title":"Diabetologia"},{"issue":"Suppl. 6","key":"10.1016\/j.autrev.2026.104091_bb0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/dom.16402","article-title":"Type 1 diabetes presenting in adults: trends, diagnostic challenges and unique features","volume":"27","author":"Evans-Molina","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0460","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/diabetes.48.3.460","article-title":"Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study","volume":"48","author":"Ziegler","year":"1999","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0465","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1210\/jcem.87.3.8343","article-title":"Glutamic acid decarboxylase antibody positivity is associated with an impaired insulin response to glucose and arginine in nondiabetic patients with autoimmune thyroiditis","volume":"87","author":"Lethagen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0470","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/db09-0747","article-title":"GAD antibody positivity predicts type 2 diabetes in an adult population","volume":"59","author":"Lundgren","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2026.104091_bb0475","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eplepsyres.2015.05.008","article-title":"Visit to jazz concert by Brad Mehldau & hr-Bigband (06.03.2026)","volume":"115","author":"Keezer","year":"2015","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0480","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/pedi.13034","article-title":"Type 1 diabetes and epilepsy in childhood and adolescence: do glutamic acid decarboxylase autoantibodies play a role? Data from the German\/Austrian\/Swiss\/Luxembourgian DPV registry","volume":"21","author":"de Sousa","year":"2020","journal-title":"Pediatr Diabetes"},{"issue":"9","key":"10.1016\/j.autrev.2026.104091_bb0485","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/81.9.1207","article-title":"Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction","volume":"81","author":"Pittock","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2026.104091_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1533748","article-title":"Teplizumab: a promising intervention for delaying type 1 diabetes progression","volume":"16","author":"Saleem","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0495","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/bbrc.2001.5754","article-title":"Developmental expression and localization of IA-2 mRNA in mouse neuroendocrine tissues","volume":"288","author":"Shimizu","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0500","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/002215540104900610","article-title":"Expression of the protein tyrosine phosphatase-like protein IA-2 during pancreatic islet development","volume":"49","author":"Roberts","year":"2001","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0505","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/CON.0000000000001079","article-title":"Autoimmune-associated seizures","volume":"28","author":"Gillinder","year":"2022","journal-title":"Continuum"},{"key":"10.1016\/j.autrev.2026.104091_bb0510","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yebeh.2018.03.004","article-title":"Anti-GAD antibodies in a cohort of neuropsychiatric patients","volume":"82","author":"Vinke","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.autrev.2026.104091_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2024.108159","article-title":"Cognitive decline in adult-onset temporal lobe epilepsy: insights from aetiology","volume":"237","author":"Hern\u00e1ndez","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10073","article-title":"Corresponding risk factors between cognitive impairment and type 1 diabetes mellitus: a narrative review","volume":"8","author":"Jin","year":"2022","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-161250","article-title":"Type 1 diabetes mellitus and cognitive impairments: a systematic review","volume":"57","author":"Li","year":"2017","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0530","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2377-13-76","article-title":"Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study","volume":"13","author":"Takagi","year":"2013","journal-title":"BMC Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0535","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.seizure.2014.04.009","article-title":"Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications","volume":"23","author":"Lilleker","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.autrev.2026.104091_bb0540","series-title":"Focal impaired awareness seizure","author":"Kumar","year":"2025"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0545","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200034","article-title":"Seizure semiology in antibody-associated autoimmune encephalitis","volume":"9","author":"Kaaden","year":"2026","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0550","doi-asserted-by":"crossref","first-page":"40","DOI":"10.17749\/2077-8333\/epi.par.con.2025.215","article-title":"Bilateral tonic-clonic seizures and status epilepticus in autoimmune encephalitis","volume":"17","author":"Maximova","year":"2025","journal-title":"Epilepsiia Paroksizmal\u2019nye Sostoianiia"},{"key":"10.1016\/j.autrev.2026.104091_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123288","article-title":"Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: clues of a temporal plus network","volume":"467","author":"Morano","year":"2024","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0560","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.55730\/1300-0144.5749","article-title":"Electroencephalographic abnormalities in children with type 1 diabetes mellitus: a prospective study","volume":"53","author":"Yildirim","year":"2023","journal-title":"Turk J Med Sci"},{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0565","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1007\/s00415-024-12385-2","article-title":"Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study","volume":"271","author":"Fonte","year":"2024","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104091_bb0570","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.neurol.2024.08.006","article-title":"MRI findings in autoimmune encephalitis","volume":"180","author":"Hartung","year":"2024","journal-title":"Rev Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0575","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00234-024-03318-x","article-title":"Autoimmune encephalitis: what the radiologist needs to know","volume":"66","author":"Sanvito","year":"2024","journal-title":"Neuroradiology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0580","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jpeds.2008.03.005","article-title":"Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus","volume":"153","author":"Ho","year":"2008","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.autrev.2026.104091_bb0585","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/db19-1100","article-title":"Structural alterations in deep brain structures in type 1 diabetes","volume":"69","author":"Filip","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0590","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41419-023-05909-7","article-title":"High glucose induces tau hyperphosphorylation in hippocampal neurons via inhibition of ALKBH5-mediated Dgkh m6A demethylation: a potential mechanism for diabetic cognitive dysfunction","volume":"14","author":"Qu","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2026.104091_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2020.113287","article-title":"Hyperglycemia induces RAGE-dependent hippocampal spatial memory impairments","volume":"229","author":"Momeni","year":"2021","journal-title":"Physiol Behav"},{"key":"10.1016\/j.autrev.2026.104091_bb0600","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3389\/fneur.2019.00804","article-title":"Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis","volume":"10","author":"Blinder","year":"2019","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0605","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10072-021-05281-4","article-title":"Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?","volume":"43","author":"Lacruz Ballester","year":"2022","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0610","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0615","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200090","article-title":"Antibodies against glutamic acid decarboxylase 65 are locally produced in the CSF and Arise during affinity maturation","volume":"10","author":"Biljecki","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0620","doi-asserted-by":"crossref","first-page":"200","DOI":"10.17712\/nsj.2020.3.20190057","article-title":"Epilepsy in patients with insulin-dependent diabetes and relation to glutamic acid decarboxylase 65","volume":"25","author":"Mahmoud","year":"2020","journal-title":"Neurosciences (Riyadh)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0625","first-page":"406","article-title":"Evaluation of the association of glutamic acid decarboxylase antibody and limbic encephalitis in children with type 1 diabetes mellitus","volume":"91","author":"Ugurlu","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0630","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s11606-019-04835-9","article-title":"Stiff person syndrome and type 1 diabetes mellitus: a case of the chicken or the egg?","volume":"34","author":"Rathbun","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0635","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2169\/internalmedicine.1289-18","article-title":"Hashimoto\u2019s encephalopathy presenting with smoldering limbic encephalitis","volume":"58","author":"Nagano","year":"2019","journal-title":"Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0640","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s13760-021-01747-6","article-title":"Limbic encephalitis and subclinical Hashimoto\u2019s disease associated with anti-GAD and anti-titin antibodies in a case of prostate cancer","volume":"122","author":"Karsidag","year":"2022","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0645","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030422","article-title":"Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine","volume":"13","author":"Popoviciu","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0650","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-022-01826-9","article-title":"Immune mechanisms in Epileptogenesis: update on diagnosis and treatment of autoimmune epilepsy syndromes","volume":"83","author":"Flammer","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104091_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1248919","article-title":"Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options","volume":"14","author":"Daetwyler","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0660","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-253696","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab","volume":"16","author":"Zand Irani","year":"2023","journal-title":"BMJ Case Rep"},{"issue":"21","key":"10.1016\/j.autrev.2026.104091_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213571","article-title":"Cancer therapy-induced encephalitis","volume":"16","author":"Desbaillets","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.autrev.2026.104091_bb0670","series-title":"Paraneoplastic limbic encephalitis","author":"Altabakhi","year":"2025"},{"issue":"8","key":"10.1016\/j.autrev.2026.104091_bb0675","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","article-title":"Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies","volume":"72","author":"Ari\u00f1o","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104091_bb0680","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.seizure.2020.05.008","article-title":"Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy","volume":"80","author":"Tizazu","year":"2020","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0685","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.55.1.46","article-title":"Autoantibodies to glutamic acid decarboxylase in patients with therapy resistant epilepsy","volume":"55","author":"Peltola","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0690","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41420-025-02459-z","article-title":"Immunotherapy for autoimmune encephalitis","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0695","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s13311-021-01178-4","article-title":"Antibody therapies in autoimmune encephalitis","volume":"19","author":"Smets","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"14","key":"10.1016\/j.autrev.2026.104091_bb0700","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.cell.2022.06.025","article-title":"Structural mechanisms of GABA(A) receptor autoimmune encephalitis","volume":"185","author":"Noviello","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104091_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.990553","article-title":"Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: clinical spectrum and prognosis of a cohort from China","volume":"13","author":"Bai","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2026.104091_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120540","article-title":"Glutamic acid decarboxylase antibody-associated neurological syndromes: clinical and antibody characteristics and therapy response","volume":"445","author":"Madlener","year":"2023","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0715","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0720","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00415-020-10250-6","article-title":"Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data","volume":"268","author":"Rada","year":"2021","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104091_bb0725","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0730","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/1744666X.2023.2281990","article-title":"Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function","volume":"20","author":"Fanaropoulou","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104091_bb0735","doi-asserted-by":"crossref","first-page":"22","DOI":"10.17925\/EE.2023.19.2.7","article-title":"Teplizumab in type 1 diabetes mellitus: an updated review","volume":"19","author":"Thakkar","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0740","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0213-9626(10)70003-2","article-title":"Stiff person syndrome and cerebellar ataxia associated with glutamic acid decarboxylase antibodies and type 1 diabetes: what is the link between neurological diseases and autoimmunity to the beta cell?","volume":"29","author":"Vives-Pi","year":"2010","journal-title":"Inmunolog\u00eda"},{"issue":"7","key":"10.1016\/j.autrev.2026.104091_bb0745","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00415-020-09782-8","article-title":"Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies","volume":"267","author":"Mu\u00f1iz-Castrillo","year":"2020","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104091_bb0750","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.2337\/dc11-0981","article-title":"A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in diabetes prevention trial-type 1 (DPT-1) participants","volume":"34","author":"Sosenko","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.autrev.2026.104091_bb0755","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s13311-022-01188-w","article-title":"Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.autrev.2026.104091_bb0760","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13311-019-00796-3","article-title":"Anti-neuronal antibodies within the IVIg preparations: importance in clinical practice","volume":"17","author":"Dimitriadou","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2026.104091_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1632690","article-title":"Association of systemic inflammatory factors with clinical outcomes in patients with autoimmune encephalitis at different clinical stages","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104091_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577779","article-title":"Immunological predictors for the outcome in patients with antibody-mediated autoimmune encephalitis","volume":"362","author":"Chen","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104091_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1738062","article-title":"Prognostic factors and a preliminary prognostic model in anti-GAD antibody-associated epilepsy","volume":"17","author":"Bai","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104091_bb0780","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2021.09.007","article-title":"Predictors and prognoses of epilepsy after anti-neuronal antibody-positive autoimmune encephalitis","volume":"92","author":"Chen","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.autrev.2026.104091_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120766","article-title":"Drug-resistant epilepsy: definition, pathophysiology, and management","volume":"452","author":"Mesraoua","year":"2023","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0790","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/epi.15612","article-title":"Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: a consensus report from the international league against epilepsy neuroimaging task force","volume":"60","author":"Bernasconi","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.autrev.2026.104091_bb0795","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.51566","article-title":"Hyperventilation-induced focal seizures in adults: think autoimmune encephalitis","volume":"9","author":"Wennberg","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104091_bb0800","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/arclin\/acac001","article-title":"Neuropsychological performance in autoimmune limbic encephalitis: evidence from an immunotherapy-na\u00efve cohort","volume":"37","author":"Mueller","year":"2022","journal-title":"Arch Clin Neuropsychol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104091_bb0805","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-024-06205-5","article-title":"Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes","volume":"67","author":"Phillip","year":"2024","journal-title":"Diabetologia"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:43:21Z","timestamp":1785167001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1568997226001059"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104091","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104091"}}